Efficacy and safety of combination therapy with lenvatinib and pembrolizumab in elderly patients with advanced endometrial cancer

Background. Currently, women over 65 years of age comprise a quarter of endometrial cancer (EC) patients, but this population remains underrepresented in clinical trials. The combination therapy with lenvatinib plus pembrolizumab has demonstrated a significant improvement in progression-free survival and overall survival in patients with mismatch repair system proficiency (pMMR/MSS) after a single prior treatment line. However, data on the efficacy and safety of this regimen in real-world clinical practice, especially in elderly patients, are limited.

Aim. To describe the efficacy and safety of EC therapy with lenvatinib and pembrolizumab in elderly patients.

Materials and methods. In this retrospective single-center study conducted at a Moscow hospital (December 2020 – March 2024), we collected data on the efficacy and safety of lenvatinib and pembrolizumab therapy in 26 patients over 65 years of age. Patients with pathologically confirmed EC without evidence of microsatellite instability were included. The primary endpoint of the study was progression-free survival; additionally, we evaluated the clinical characteristics of the patients, analyzed the objective response rate and the incidence of adverse events.

Results. The median age was 69 (65–81) years, 23 % of patients were older than 75 years. The performance status of 92.3 % of patients was classified as ECOG 0–1, endometrial adenocarcinoma was the most frequently detected type (61.5 % of cases), serous carcinoma was reported in 10 (38.5 %) patients. The median number of prior treatment lines was 3 (2–6). The objective response rate reached 25 %, and the disease control rate was 75 %. The median progression-free survival was 5.67 (1.4–35.3) months. Adverse events of any grade were noted in 24 (92.3 %) patients. Lenvatinib dose reduction was performed in 76.9 % of cases. The most frequent adverse events were arterial hypertension (in 16 (61.5 %) patients), fatigue (in 5 (19.2 %) patients), and diarrhea (in 3 (11.5 %) patients).

Conclusion. In this real-world clinical practice study in Russia involving patients with recurrent and metastatic EC without mismatch repair system deficiency (pMMR/MSS) over 65 years of age who received lenvatinib plus pembrolizumab, the efficacy and safety of the treatment were comparable to those reported in earlier studies, suggesting the feasibility of combination therapy in this population with appropriate attention to performance status and management of adverse events. Additional studies are required to evaluate the efficacy and safety of the combination therapy of lenvatinib and pembrolizumab in patients with a more severe functional status.

1. Ponomareva N.N. The process of demographic aging: essence, features and consequences in the countries of the world. Vestnik Novosibirskogo gosudarstvennogo pedagogicheskogo universiteta = Bulletin of the Novosibirsk State Pedagogical University 2013;6(16):58–65. (In Russ.).

2. Yuansin V. Analysis of trends and current state of population aging in Russia. Gumanitarnye, socialno-ekonomicheskie i obshchestvennye nauki = Humanities, Socio-Economic and Social Sciences 2024;(12):1–4. (In Russ.).

3. Malignant neoplasms in Russia in 2015 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: Moskovskiy nauchno-issledovatelskiy onkologicheskiy institut im. P.A. Gertsena – filial FGBU “Natsionalnyy meditsinskiy issledovatelskiy tsentr radiologii” Minzdrava Rossii, 2017. 250 p. (In Russ.).

4. Malignant neoplasms in Russia in 2023 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: Moskovskiy nauchno-issledovatelskiy onkologicheskiy institut im. P.A. Gertsena – filial FGBU “Natsionalnyy meditsinskiy issledovatelskiy tsentr radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).

5. Alemdaroglu S. Prognostic factors of endometrial cancer in the elderly patient group and their effects on survival. North Clin Istanbul 2020;8(4):345–53. DOI: 10.14744/nci.2020.47154

6. Bouchardy C., Rapiti E., Blagojevic S. et al. Older female cancer patients: Importance, causes, and consequences of undertreatment. J Clin Oncol 2007. DOI: 10.1200/JCO.2006.10.4208

7. Talarico L., Chen G., Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004. DOI: 10.1200/JCO.2004.02.175

8. Jatoi A., Hillman S., Stella P. et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005. DOI: 10.1200/JCO.2005.03.7465

9. Makker V., Aghajanian C., Cohn A.L. et al. A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (study 111/KEYNOTE-146): Long-Term efficacy and safety update. J Clin Oncol 2023. DOI: 10.1200/JCO.22.01021

10. Makker V., Colombo N., Casado Herráez A. et al. Lenvatinib plus Pembrolizumab for advanced endometrial cancer. N Engl J Med 2022. DOI: 10.1056/nejmoa2108330

11. Makker V., Taylor M.H., Aghajanian C. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020. DOI: 10.1200/JCO.19.02627

12. Rumyantsev A.A., Protasova A.E., Sheremet M.Yu. et al. Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2023;19(4):104–13. (In Russ.). DOI: 10.17650/1994-4098-2023-19-4-104-113

13. Nagao S., Nishio S., Michimae H. et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol 2013. DOI: 10.1016/j.ygyno.2013.09.021